Cover Image


Immediate Release Pain Management to 2020

出版商 Greystone Research Associates 商品编码 302703
出版日期 内容信息 英文
商品交期: 最快1-2个工作天内
Back to Top
速放性疼痛管理的预测 Immediate Release Pain Management to 2020
出版日期: 2014年05月21日 内容信息: 英文





  • 进化的疼痛管理通信协议
  • 人口动态与疾病
  • 疼痛管理的地区性差异
  • 速放性疼痛管理
  • 癌症突发性疼痛
  • 目前环境
  • 未满足需求与市场机会


  • 口颊片、口含锭
  • 口腔喷雾
  • 舌下含片
  • 鼻喷雾


  • 支持市场
  • 人口动态和成长率
  • 竞争的药物类别
  • 市场预测


  • 粘膜速放性Fentanyl(TIRF:Transmucosal immediate-release fentanyl)
  • 口服药
  • Abstral
  • Actiq
  • Fentora/Effentora
  • Onsolis/Breakyl
  • Subsys
  • 非专利速放性Fentanyl
  • 鼻腔药
  • Instanyl
  • Lazanda


  • Alfentanil
  • Sufentanil
  • 潜在性竞争药物治疗


  • 法律规章
  • 独自制剂及技术
  • 联盟、联盟


Product Code: PMP492R

As life expectancy in the developed world increases and populations age, the incidence and associated morbidity of chronic and acute pain is increasing and placing a higher level of emphasis on pain management as a quality-of-life issue for patients and their families. Responding to this trend, drug developers are increasingly turning to alternative formulations of pain management drugs. Because it has the potential to improve drug therapy compliance, transmucosal pain management addresses a key healthcare issue - one that is particularly problematic in aging populations and developing economies. We expect this market to experience healthy growth through 2020 as absorbable solid dosage technology is applied to existing drugs, and as similar formulations become an important route of administration for novel pain drugs


  • Analyzes and evaluates the global market opportunity for immediate release pain management and assesses the probable impact of evolving regulatory, economic and demand factors
  • Assesses immediate release products approved or in development for the delivery of therapeutic pain management drugs
  • Provides detailed descriptions of pain management treatment segments, market factors, and business strategies
  • Forecasts immediate release pain management product demand to 2020
  • Profiles sector companies, their product development activities, supply chain partners, business strategies, and collaboration partners

Table of Contents

  • Executive Summary
  • The Pain Management Market
  • Evolving Pain Management Protocols
  • Demographics and Disease
  • Regional Differences in Pain Management
  • Immediate Release Pain Management
  • Breakthrough Cancer Pain
  • The Current Landscape
  • The Unmet Need and Opportunity
  • Immediate Release Formulation Technologies
  • Buccal Films and Tablets
  • Oral Sprays
  • Sublingual Tablets
  • Nasal Sprays
  • The Market for Breakthrough Cancer Pain
  • The Addressable Market
  • Market Demographics and Growth
  • Competing Drug Classes
  • Market Projections
  • Product Analysis, Market Position Historical Revenue & Forecasts
  • Transmucosal Immediate-Release Fentanyl (TIRF)
  • Oral
  • Abstral
  • Actiq
  • Fentora/Effentora
  • Onsolis/Breakyl
  • Subsys
  • Generic Immediate Release Fentanyl
  • Nasal
  • Instanyl
  • Lazanda
  • Development-Stage IR Pain Management Drugs
  • Alfentanil
  • Sufentanil
  • Potential Competing Drug Therapeutics
  • Market Factors
  • Regulatory Factors
  • Proprietary Formulations & Technology
  • Collaborations & Alliances
  • Company Profiles
Back to Top